Nigeria has taken delivery of its first supply of lenacapavir, a long-acting injectable for HIV prevention. This development represents a significant shift in the country's approach to combating one of the world's largest HIV epidemics.
How Lenacapavir Works
Lenacapavir is administered as a subcutaneous injection once every six months. Unlike daily oral PrEP (pre-exposure prophylaxis), which requires consistent daily adherence, this new regimen simplifies HIV prevention to two clinic visits annually. The injection works by targeting the HIV capsid, a structural protein of the virus that is less prone to mutation. This mechanism may make lenacapavir more durable against diverse HIV strains—a critical factor in Nigeria's epidemic landscape.
Why This Matters for Nigeria
With approximately 1.8 million people living with HIV, Nigeria accounts for nearly 10% of the global HIV burden outside of eastern and southern Africa. While treatment and prevention efforts have expanded, adherence barriers remain substantial. Daily pills can be challenging for individuals facing stigma, privacy concerns, or unstable living conditions. A long-acting option could significantly increase protection among key populations, including adolescents, sex workers, and people in mobile occupations.
The Road Ahead
Securing the drug supply is only the initial phase. Successful implementation will require:
- Developing distribution networks to ensure equitable access
- Training healthcare providers on administration and counseling
- Establishing clear guidelines for priority populations
- Creating robust monitoring systems to track effectiveness and side effects
Public health experts emphasize that lenacapavir should complement, not replace, existing prevention tools. Condoms, regular testing, and oral PrEP remain essential components of a comprehensive HIV strategy.
Looking Forward
As Nigeria begins this new chapter in HIV prevention, all eyes will be on rollout efficiency and real-world effectiveness. If successful, lenacapavir could serve as a model for other high-burden countries seeking to accelerate progress toward epidemic control.
